Compare Charles River Laboratories Intl. Inc (CRL) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Shell PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Shell PLC trades at $84.64 (market cap $230.24B). The key difference: Shell PLC is far larger — about 20.7× Charles River Laboratories Intl. Inc's market cap, and Shell PLC pays a 3.7% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SHEL | |
|---|---|---|
Market Cap | $11.14B | $230.24B |
Sector | Health | Energy |
52-Week High | $233.60 | $94.15 |
52-Week Low | $145.57 | $70.28 |
Enterprise Value | $14.00B | $282.77B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Shell (SHEL) trades at $83.98, up 2.13% in the last session, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations at $2.44 EPS, while Q2 2026 is projected at $2.88. Valuation metrics appear attractive with a P/E of 13.08 and P/S of 0.92. News highlights include the ARC Resources acquisition approval and Venezuela gas field developments, indicating strategic growth initiatives.
The outlook for SHEL is positive, supported by robust cash flows, a 69% buy rating from analysts, and a consensus price target of $122.20. Risks include declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and geopolitical disruptions in Middle East production. Investors may find value in its dividend yield and LNG market exposure, though macroeconomic volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
